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IN a series of investigations using tumours which were originally induced with
methylcholanthrene in inbred rats, it was shown that atrophy and regression of
tumours caused by restricting their blood supply rendered the cured rats immune
to subsequent inoculations of tumour, (Lewis, Maxwell and Aptekman, 1951;
Lewis andAptekman, 1952). Attemptsto confirmtheseexperimentsusingtumours
which arose spontaneously in inbred strains of mice and had been subpassaged
only a few times in animals oftheir strain oforigin were unsuccessful (Fardon and
Prince, 1953; Foley, 1953a) and it was suggested that the success of the earlier
studies ofLewis and Aptekman (1952) was due to the presence of immunogenetic
differences between tumour and host which probably arose during repeated
transplantation oftumour. Later, however, Foley (1953b) showed that immunity
could be induced in C3H mice following regression of tumours originally induced
with methylcholanthrene, and so it would seem that the immune response evoked
following tumour atrophy varies with the two types of tumour.
The development of tumour immunity in inbred rats following atrophy and
regression of tumours originally induced with methylcholanthrene has been
re-investigated and in the following experiments, a number oftumours have been
studied at different stages oftheir transplantation history in an effort to determine
the nature of the antigenic stimulus producing this immunity.
MATERIALS AND METHODS.
The tumours described in a previous paper (Baldwin, 1955), together with
three additional tumours, were used in the present experiments. These tumours
were induced with methylcholanthrene in rats of selected inbred litters and each
tumour was transplanted only into the offspring produced by mating litter mates
of the tumour donor rat. The new tumours were designated as follows:
Sarcoma S67: A very hard tumour which reached palpable size within 12 days
of implantation in Group II rats and then grew very slowly until host rats had to
be killed within 6 to 10 weeks.
SarcomaS606 (Group 13rats) andSarcoma S609 (Group 12 rats): Bothtumours
were moderately active, growing to palpable size within 8 days of implantation.
Ratsbearing these tumours became moribund within 4 to 6 weeks and were killed.
EXPERIMENTAL METHODS.
The technique oftumour transplantation has been fully described in a previous
paper (Baldwin, 1955). Rats bearing tumour grafts consisting of approximatelyIMMUNITY FOLLOWING REGRESSION OF TUMOURS
one half trocar full.of tumour tissue were examined three times a week; tumour
sizes being measured in three dimensions. When engrafted tumours reached a
size of approximately 20 X 10 x 10 mm. (Table I), they were ligated so as to
restrict their blood supply. This was achieved in anaesthetised rats by firmly
drawing a loop ofsuture nylon under the base ofthe tumour which was lifted free
from the muscles on the back ofthe rat so that the tumour was enclosed within a
fold of loose skin. Further loops of nylon were placed around the skin pockets at
24hourintervals untilthetumoursregressed. Tumours usuallybecamediscoloured
and considerably swollen within 24 hours of ligation. Then, following absorption
of the tumours, the skin pockets slowly dried up over several days, leaving small
scars at the tumour implant sites.
Rats in which ligated tumours had regressed were challenged for immunity 3 to
4 weeks later by re-implantation of the appropriate tumour. Challenge grafts
TABLE I.-Inhibition of Tumour Growthfollowing Ligation of
Transplanted Tumours in I"bred Rats.
Number of days
tumour had grown
before treatment.
6
5
4
5
3
4
4
4
17
10
10-14
8
10
5
1.0
7-10
7
6
8
7-10
5
6--8
Number of
tumour-bearing
rats treated.
5
19
6
30
10
9
11
11
7
48
3
9
17
12
9
50
3
14
15
11
43
8
11
16
4
39
13
223
Tumour and
litter of
origin.
S5
(Group B)
S69
(Group I)
S67
(Group II)
S66
(Group III)
S609
(Group 12)
S606
(Group 13)
Total
Transplant
generation
treated.
19
20
22
9
16
19
25
26
4
5
6
7
8
8
9
10
12
2
3
4
6
2
Number of
tumours
regressing.
5
19
6
30
5
6
11
6
6
34
3
9
17
12
9
50
2
14
12
10
38
8
11
-15
4
38
12
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were made in the left side of the rat and were approximately half the size of the
initial implant. Any rats proving to be resistant to the challenge grafts were
re-implantedwith large amounts oftumour (1 to 2 trocars full) 1 to 2 monthslater
and kept under observation for at least 6 months. During this time the tumour
implantation sites were examined twice weekly, and at the conclusion of each
experiment a number of rats were examined for metastatic growth.
RESULTS.
The results of experiments in which transplanted tumours in inbred rats were
ligated in skin pockets so as to occlude their blood supply are recorded in Table I.
In most cases it was possible to isolate completely the small progressively growing
tumour grafts and so obstruct their blood supply. Occasionally, however, tumour
grafts invaded the muscle tissue of the host so that it was not possible to ligate
the whole tumour. In these experiments the tumours continued to grow even
though the treatment destroyed practically all ofthe original tumour grafts. This
often happened in experiments with the rapidly growing tumour S69 and also
occasionally with tumour S66 (Table I).
The results recorded in Table II show that out of 197 rats in which tumours
had regressed as a result ofligation only 77 (39 per cent) were resistant to the first
challenge graft of the original tumour. However, the immune response evoked
following atrophy and regression ofthe different tumours varied considerably and
appeared to be related to the growth rate ofthe tumours. Thus regresssion ofthe
rapidly growing tumour S69 induced tumour resistance in only 1 cured rat (3 per
cent) and regression of two other fast-growing tumours, S5 and S606, produced
similar results. In contrast, experiments performed with tumour S67, which had
a relatively slow growth rate, were nearly always successful, immunity being
producedin 76 per cent of the cured rats. The results obtained with tumours S66
and S609 were more variable, although approximately one half of the cured rats
were found to be resistant to tumour growth.
AsshowninTable II, repeatedtransplantation oftumourhadnogreatinfluence
ontheabilityofatrophyingtumourtoinduce aresistant state. Thusinexperiments
with tumour S67, it was found that immunity could be induced using tumour
grafts from the 4th to the 8th generation oftransfer. Similar results were obtained
in experiments where regression oftumour induced little or no tumour resistance.
For example, regression of grafts of tumour S69 from between the 9th and 26th
generation induced a resistant state in only one rat.
Most ofthe rats in which the first challenge graft had failed to growwerefound
to be immune to re-implantation with large doses ofthe appropriate tumour, and
out of 77 rats challenged only 3 (4 per cent) proved to be susceptible to tumour
growth.
DISCUSSION.
The results obtained in the above experiments confirm the findings of Lewis
and Aptekman (1952) andFoley (1953b) regarding the development ofimmunityin
inbred animals to transplanted tumours originally induced with methylcho-
lanthrene. However, theimmune responseevokedfollowing atrophyandregression
ofdifferent tumours was found to vary considerably, depending upon their growth
rate. Thus regression of rapidly-growing tumours as a result of ligation induced
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TABLE II.-Development of Tunour Immunity in Inbred Rats following Induced
Regression of Tumours Originating in the Same Strain.
Number of
cured rats
immune upon Per cent
re-implantation. immune.
3
2
0
5 . 17
Transplant
generation Number of
of tumour used untreated
for challenge rats
graft. inoculated.*
19 . 3
21 . 8
23 . 8
19
14
17
21
26
27
0
0
1
0
0
1
3
9
15
5
5
37
1
8
0
8
17
8
6
1
2
17
0
77
3
5
5
6
7
8
76
8
9
10
10
4
6
10
5
35
9
4
4
5
3
25
5
9
4
10
28
4
9
3
3
19
2
47
2
3
4
7
45
0
39 128
* Tumour grew in all untreated animals.
little or no tumour immunity, whereas treatment of tumour S67, which has a slow
growth rate, rendered nearly all the cured hosts resistant to further implants ofthe
original tumour. It should be pointed out that the method of testing for tumour
immunity by re-implantation of tumour is an all-or-none technique which will
not detect slight levels ofresistance. In addition, the minimum level ofresistance
which will protect a cured host against re-implants of tumour will depend in part
upon the growth rate or " virulence " ofthe tumour, and so this may explain why
experiments with rapidly-growing tumours were unsuccessful.
The nature of the antigenic stimulus evoking an immune response following
regression of transplanted tumour in inbred animals is still unknown, although it
Transplant
generation
used for
first graft.
19
20
22
9
16
19
25
26
4
5
6
7
8
8
9
10
12
2
3
4
6
2
Tumour and
litter of
origin.
S5
(Group B)
S69
(G-roup I)
867
(Group II)
S66
(Group III)
S609
(Group 12)
S606
(Group 13)
Total
Number of
rats in which
tumours had
regressed. r
5
19
6
30
* 5
6
9
6
6
32
3
9
16
12
9
49
2
14
12
8
36
8
11
16
3
38
12
197
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is nowgenerally assumed that immunogenetic differences between tumour andhost
rather than specific tumour antigens are responsible for the induction of tumour
immunity (Hauschka, 1952; Eichwald, 1953; Cohen andCohen, 1954). Evidence
to support this assumption has been obtained by Foley (1953a, 1953b), who showed
that immunity could be induced in inbred mice against transplanted tumours
which were induced originally with methylcholanthrene, but not against tumours
which originated spontaneously in the same strain of mice.
According to Hauschka (1952) these immunogenetic differences arise during
repeated subpassaging of tumour over long periods of time by mutation of either
the tumour or host strain ofanimals. Although heterogeneity in the host strain of
animals cannot be ruled out as a contributory factor, Foley (1953a) showed that
this factor did not influence the immune response induced in mice following
regression of transplanted tumours which arose spontaneously, and no immunity
was produced. Repeated subpassaging of tumour also appears to have no great
influence on the ability of atrophying tumour to induce tumour resistance, and in
the present experiments, as well as those ofFoley (1953b), it was possible to induce
immunity before repeated tumour transplants had been made. Similarly, in the
present study, attempts to induce immunity against a rapidly-growing tumour,
S69, were nearly always unsuccessful even though experiments were performed
with tumour grafts from between the 9th and 26th generation of transfer.
Thus if the induction of tumour immunity depends upon immunogenetic
differences between tumour and host, then it would seem that the original induced
tumour represents a mutated tissue capable ofeliciting an immune response when
implanted into the host strain of animals. This suggestion will require further
study however, especially in view of Burdette's rbcent criticism of the correlation
between mutagenicity and carcinogenicity of chemical compounds (Burdette,
1955).
A number of techniques have been described recently by which the antibody
response to tumour inoculation can be determined. These include agglutination
reactions using erythrocytes (Gorer and Mikulska, 1954) and leucocytes (Amos,
1953) and the anaphylaxis technique which was used by Fink, Snell and Kelton
(1953) to determine the antibody response ofBalb. C mice following inoculation of
an homologous tumour. It may well be that the application of these techniques
to the study of the antigenic structure of transplanted tumours which originated
spontaneously or were induced with methylcholanthrene in inbred animals will
disclose the nature of the antigenic stimulus producing immunity following
induced regression of the latter type of tumour.
SUMMARY.
Immunity to transplanted tumours originally inducedwithmethylcholanthrene
has been produced ininbred rats following atrophy and regression oftumour grafts
ligated so as to restrict their blood supply.
The immune response evoked following regression oftumour was found to vary
considerably with different tumours. In some cases regression of tumour induced
immunityinpracticallyallcuredrats, whereaswithothertumoursnoneofthecured
rats were resistant to re-implants of the original tumour. Repeated subpassaging
of tumour did not influence the ability of atrophying tumour to induce tumour
resistance, and in cases where it was possible to induce immunity experiments
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performed with tumours which had been transplanted only a few times were
successful.
It is suggested that the antigenic stimulus producing immunity to transplanted
tumours which were originally induced in inbred rats with methylcholanthrene
depends upon immunogenetic differences between tumour and host, and the
origin of these differences is discussed.
The author wishes to thank Dr. M. R. Lewis, The Wistar Institute ofAnatomy
and Biology, for her help and advice and Professor G. J. Cunningham, Royal
College of Surgeons, for examining the histological sections. Thanks are also due
to Miss M. E. Gillard for invaluable technical assistance.
This work was supported bytheNottinghamshire Branch ofthe British Empire
Cancer Campaign.
REFERENCES.
AMos, D. B.-(1953) Brit. J. e.xp. Path., 34, 464.
BALDWIN, R. W.-(1955) Brit. J. Cancer, 9, 646.
BURDETTE, W. J.-(1955) Cancer Res., 15, 201.
COHEN, A. AND COHEN, L.-(1954) Brit. J. Cancer, 8, 313.
EICHWALD, E. J.-(1953) J. nat. Cancer Inst., 14, 705.
FARDON, J. C. AND PRINCE, TJ. E.-(1953) Cancer Res., 13, 9.
FINI,MI. A., SNELL, G. D. AND KELTON, D.-(1953) Ibid., 13, 666.
FOLEY, E. J.-(1953a) Ibid., 13, 578.---(1953b) Ibid., 13, 835.
GORER, P. A. AND MIRULSKA, Z. B.-(1954) Ibid., 14, 651.
HAUSCHKA, T. S.-(1952) Ibid., 12, 615.
LEwIs, M. R. AND APTEKMAN, P. M.-(1952) Cancer, 5, 411.
Idern, MAXWELL, D. B. AND APTEKMAN, P. M.-(1951) Surlcery, 30, 689.